Apalutamide/ADT Demonstrates 100% Biochemical RFS Rate in High-Risk Prostate Cancer
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer
Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer